209 assets in Breast Carcinoma

Therapeutic assets addressing Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adrelumab Breast Carcinoma	Fudan University	P2	NR ()
arx788 Breast Carcinoma	Laura Huppert, MD, BA	P2	NR ()
Gtaexs617 Breast Carcinoma	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1/2	NR ()
ide574 Breast Carcinoma	IDEAYA Biosciences	P1	NR ()
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer Breast Carcinoma	Dana-Farber Cancer Institute	P1	NR ()
Inv-6452 Breast Carcinoma	Shenzhen Ionova Life Sciences Co., Ltd.	P1/2	NR ()
Revaree Plus Breast Carcinoma	Memorial Sloan Kettering Cancer Center	P4	NR ()
SH3765 Breast Carcinoma	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P1	NR ()
tfx06 Breast Carcinoma	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	NR ()

Showing 201 to 209 of 209 assets

PreviousPage 5 of 5Next